Login to Your Account

Rebiotix Seeking to Pioneer Microbiota Restoration

By Marie Powers
Staff Writer

Friday, September 27, 2013
Rebiotix Inc. has sprinted from concept to clinical application in less than two years in pursuit of treatment for gastrointestinal diseases, such as recurring Clostridium difficile infection (CDI), using the human microbiome – the collective genomes of the human microbiota. In July, the FDA approved the Roseville, Minn.-based company’s investigational new drug application for lead candidate RBX2660 (microbiota suspension).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription